Navigation Links
Kosan in Medical News

Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors

...s currently a Director and Chief Executive Officer of privately held TRF Pharma, Inc. Previously, she was the Chief Executive Officer and President of kosan Biosciences Incorporated where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...armaceuticals, Inc., Bristol-Myers Squibb Company, kosan Biosciences, Inc., Celgene Corporation, F. Hoffman...ual Agreement II-47 Bristol-Myers to Take Over kosan Biosciences II-47 Bristol and PDL BioPharma En...5 Bristol-Myers Squibb Company (USA) II-55 kosan Biosciences, Inc. (USA) II-55 Celgene Corporat...

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

... kosan Leads Industry with Most Advanced Hsp90 Inhibitor ... HAYWARD, Calif., Jan. 3 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an... single prior course of treatment (first-relapse). kosan has completed both a Special Protocol Assessment w...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

... HAYWARD, Calif., Nov. 2 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) will ann...n dial 617.801.6888, access code: 98027185. About kosan kosan Biosciences is a biotechnology company advancing t...
Kosan in Medical Technology

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...emedications and ease of pharmacist preparation. kosan anticipates conducting additional studies with tan...s trastuzumab will continue on study per protocol. kosan does not plan to enroll additional patients in thi...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

... HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...of the University of Pennsylvania. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...AYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...all of the leukemia models tested. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...AYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...disease in many additional tumors. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...HAYWARD, Calif., Jan. 15 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...t cancer represents a major market opportunity for kosan that we intend to pursue," said Robert G. Johnson,...hree weeks out of four weeks in repeated cycles. kosan is also testing alvespimycin delivered orally in a...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...d to be progression-free survival. About Kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...pending on data from expanded dose cohorts. About kosan kosan Biosciences is a biotechnology company advancing t...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...AYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...with reduced doses (one patient remains on study). kosan plans to continue to enroll patients at the 80 mg/...tion. Expanded Phase 1 Trial Includes Paclitaxel kosan has expanded the Phase 1 trial to add weekly dosin...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

...HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...e FDA's Special Protocol Assessment (SPA) process, kosan and the FDA have reached agreement on overall prot...-agent bortezomib. The Special Protocol Assessment kosan has completed applies to the TIME-1 trial. TIME-2,...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...ed primarily by the patient's level of M protein. kosan anticipates that the pivotal TIME-1 trial will beg...ion of cytotoxic proteins, leading to cell death. kosan reported data from a Phase 1b trial of tanespimyci...

More>>

Kosan in Biological Technology

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

...tory bodies outside the United States. Dr. Kraus joins Proteolix from kosan Biosciences (acquired by Bristol-Myers Squibb in 2008), where he served as ...velopment strategy of Kosan's oncology product portfolio. Prior to joining kosan in 2006, he was Group Director, Global Regulatory Strategy, Oncology with B...

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

... HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...ologist, most notably at Novartis. Dr. Cohen joins kosan from GE Healthcare Medical Diagnostics where she s... use in oncology drug development. About Kosan kosan Biosciences is a biotechnology company advancing t...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

... HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) announce...s will be available for two weeks. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

...AYWARD, Calif., April 25 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) will ann...7-801-6888, access code: 17626068. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

...AYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...ntial as a novel anticancer agent. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...AYWARD, Calif., March 18 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...high-value, near-term commercial opportunities." kosan anticipates incurring restructuring charges of app...40-$50 million to $37-$47 million. About Kosan kosan Biosciences is a biotechnology company advancing t...

Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer

...AYWARD, Calif., March 18 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...e Officer, effectively immediately. Ms. Kim joined kosan in January 2008 as Senior Vice President and Chief...erience, demonstrated leadership and commitment to kosan to ensure that our company can operate at the high...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...AYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) announce...n will be available for two weeks. About Kosan kosan Biosciences is a biotechnology company advancing t...ux disease (GERD). For additional information on kosan Biosciences, please visit the company's website at...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...HAYWARD, Calif., Feb. 29 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) announce...s will be available for two weeks. About Kosan kosan Biosciences is a biotechnology company advancing t...ux disease (GERD). For additional information on kosan Biosciences, please visit the company's website at...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...san's Board of Directors. Helen S. Kim, who joined kosan in January 2008 as Senior Vice President and Chief... President of Kosan. "Under Robert's leadership, kosan made the successful transition from a research-ori...
Other Tags
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... 2014 The FDA is Watching: , ... On-Demand Webinar**, Dec. 11, 2014 ? Any Time at ... focus on promotional activities is no longer limited to ... looking at websites, Twitter, journal articles, TV appearances, Facebook ... Dec. 11, for On-Demand access to Timothy Ayers and ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Every year ... their communities. AlignLife experience rapid growth in the Greenville, ... very unique opportunity. AlignLife of Simpsonville will ... offices for their first annual Toy Drive. These six ... they would support with this year's toy drive. With ...
(Date:11/22/2014)... black prom dress will never go out of fashion. BellasDress.com, ... new items of black prom gowns . Now all ... up to 70% off. People throughout the world can enjoy ... made with the best materials, can make wearers feel comfortable. ... company provides these beautiful outfits in a huge range of ...
(Date:11/22/2014)... 22, 2014 “Due to my knee replacement ... from Gurnee, Ill. “While using the ice grip attachment, I ... thought there needed to be a safer way to prevent ... BLOCK. , The SPIKE BLOCK offers added safety and stability ... help to reduce injuries and damage associated with traditional spiked ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
Other Contents